Hydrothermal formation of heavy rare earth element (HREE)– xenotime deposits at 100 °C in a sedimentary basin

Most rare earth element deposits form from magmatic fluids, but there have also been discoveries of heavy rare earth element (HREE)– enriched hydrothermal xenotime deposits within sedimentary basins. As xenotime is notoriously insoluble, the question arises as to whether these lesser-known deposits form at typical basin temperatures or by influx of much hotter magmatic-hydrothermal fluids. The Browns Range District in northern Western Australia hosts deposits of xenotime that are enriched in HREEs and also uranium. The ore bodies consist of fault-controlled hydrothermal quartz-xenotime breccias that crosscut Archean basement rocks and overlying Paleoproterozoic sandstones. Analyses of fluid inclusions show that the xenotime precipitated at remarkably low temperatures, between 100 and 120 °C, in response to decompression boiling. The inclusions contain high excess concentrations of yttrium (10−3 mol/kg), REEs (1–7 × 10−5 mol/kg), and uranium (4 × 10−5 mol/kg) in equilibrium with xenotime at these low temperatures, showing that availability of phosphate limited the amount of xenotime precipitated. The analyses further identify SO4 2– and Cl– as the ligands that facilitated the elevated REE and uranium solubilities. These findings establish that significant REE transport and deposition is feasible at basin temperatures, and hence they raise the potential of unconformity settings for REE exploration. Moreover, the aqueous metal contents support a genetic link between this type of ore fluid and world-class Proterozoic unconformity-related uranium deposits elsewhere

Improving processing by adaption to conditional geostatistical simulation of block compositions

Exploitation of an ore deposit can be optimized by adapting the beneficiation processes to the properties of individual ore blocks. This can involve switching in and out certain treatment steps, or setting their controlling parameters. Optimizing this set of decisions requires the full conditional distribution of all relevant physical parameters and chemical attributes of the feed, including concentration of value elements and abundance of penalty elements. As a first step towards adaptive processing, the mapping of adaptive decisions is explored based on the composition, in value and penalty elements, of the selective mining units. Conditional distributions at block support are derived from cokriging and geostatistical simulation of log-ratios. A one-to-one log-ratio transformation is applied to the data, followed by modelling via classical multivariate geostatistical tools, and subsequent back-transforming of predictions and simulations. Back-transformed point-support simulations can then be averaged to obtain block averages that are fed into the process chain model. The approach is illustrated with a \u27toy\u27 example where a four-component system (a value element, two penalty elements, and some liberable material) is beneficiated through a chain of technical processes. The results show that a gain function based on full distributions outperforms the more traditional approach of using unbiased estimates

Assessing the Vegetation Condition Impacts of the 2011 Drought across the U.S. Southern Great Plains Using the Vegetation Drought Response Index (VegDRI)

The vegetation drought response index (VegDRI), which combines traditional climate- and satellite-based approaches for assessing vegetation conditions, offers new insights into assessing the impacts of drought from local to regional scales. In 2011, the U.S. southern Great Plains, which includes Texas, Oklahoma, and New Mexico, was plagued by moderate to extreme drought that was intensified by an extended period of recordbreaking heat. The 2011 drought presented an ideal case study to evaluate the performance of VegDRI in characterizing developing drought conditions. Assessment of the spatiotemporal drought patterns represented in the VegDRI maps showed that the severity and patterns of the drought across the region corresponded well to the record warm temperatures and much-below-normal precipitation reported by the National Climatic Data Center and the sectoral drought impacts documented by the Drought Impact Reporter (DIR). VegDRI values and maps also showed the evolution of the drought signal before the Las Conchas Fire (the largest fire in New Mexico’s history). Reports in the DIR indicated that the 2011 drought had major adverse impacts on most rangeland and pastures in Texas and Oklahoma, resulting in total direct losses of more than $12 billion associated with crop, livestock, and timber production. These severe impacts on vegetation were depicted by the VegDRI at subcounty, state, and regional levels. This study indicates that the VegDRI maps can be used with traditional drought indicators and other in situ measures to help producers and government officials with various management decisions, such as justifying disaster assistance, assessing fire risk, and identifying locations to move livestock for grazing

Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

Background: More than half of patients with melanoma that has spread to regional lymph nodes develop recurrent disease within the first 3 years after surgery. The aim of the study was to improve disease-free survival (DFS) and overall survival (OS) with interferon (IFN) α2a with or without dacarbazine (DTIC) compared with observation alone. Patients and methods: A total of 444 patients from 42 centers of the German Dermatologic Cooperative Oncology Group who had received a complete lymph node dissection for pathologically proven regional node involvement were randomized to receive either 3 MU s.c. of IFNα2a three times a week for 2 years (Arm A) or combined treatment with same doses of IFNα2a plus DTIC 850 mg/m2 every 4-8 weeks for 2 years (Arm B) or to observation alone (Arm C). Treatment was discontinued at first sign of relapse. Results: A total of 441 patients were eligible for intention-to-treat analysis. Kaplan-Meier 4-year OS rate of those who had received IFNα2a was 59%. For those with surgery alone, survival was 42% (A versus C, P = 0.0045). No improvement of survival was found for the combined treatment Arm B with 45% survival rate (B versus C, P = 0.76). Similarly, DFS rates showed significant benefit for Arm A, and not for Arm B. Multivariate Cox model confirmed that Arm A has an impact on OS (P = 0.005) but not Arm B (P = 0.34). Conclusions: 3 MU interferon α2a given s.c. three times a week for 2 years significantly improved OS and DFS in patients with melanoma that had spread to the regional lymph nodes. Interestingly, the addition of DTIC reversed the beneficial effect of adjuvant interferon α2a therap

The price of tumor control

Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimumab-induced AEs have lead to a reduction of morbidity, e.g. due to bowel perforations. However, the spectrum of less common AEs is expanding as ipilimumab is increasingly applied. Stringent recognition and management of AEs will reduce drug-induced morbidity and costs, and thus, positively impact the cost-benefit ratio of the drug. To facilitate timely identification and adequate management data on rare AEs were analyzed at 19 skin cancer centers. Patient files (n = 752) were screened for rare ipilimumab-associated AEs. A total of 120 AEs, some of which were life-threatening or even fatal, were reported and summarized by organ system describing the most instructive cases in detail. Previously unreported AEs like drug rash with eosinophilia and systemic symptoms (DRESS), granulomatous inflammation of the central nervous system, and aseptic meningitis, were documented. Obstacles included patientś delay in reporting symptoms and the differentiation of steroid-induced from ipilimumab-induced AEs under steroid treatment. Importantly, response rate was high in this patient population with tumor regression in 30.9% and a tumor control rate of 61.8% in stage IV melanoma patients despite the fact that some patients received only two of four recommended ipilimumab infusions. This suggests that ipilimumab-induced antitumor responses can have an early onset and that severe autoimmune reactions may reflect overtreatment. The wide spectrum of ipilimumab-induced AEs demands doctor and patient awareness to reduce morbidity and treatment costs and true ipilimumab success is dictated by both objective tumor responses and controlling severe side effects

Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)

Background: Genomic profiling of tumor tissue may aid in identifying predictive or prognostic gene signatures (GS) in some cancers. Retrospective gene expression profiling of melanoma and non-small-cell lung cancer led to the characterization of a GS associated with clinical benefit, including improved overall survival (OS), following immunization with the MAGE-A3 immunotherapeutic. The goal of the present study was to prospectively evaluate the predictive value of the previously characterized GS. Patients and methods: An open-label prospective phase II trial ('PREDICT') in patients with MAGE-A3-positive unresectable stage IIIB-C/IV-M1a melanoma. Results: Of 123 subjects who received the MAGE-A3 immunotherapeutic, 71 (58.7%) displayed the predictive GS (GS +). The 1-year OS rate was 83.1%/83.3% in the GS+/GS- populations. The rate of progression-free survival at 12 months was 5.8%/4.1% in GS+/GS- patients. The median time-to-treatment failure was 2.7/2.4 months (GS+/GS-). There was one complete response (GS-) and two partial responses (GS+). The MAGE-A3 immunotherapeutic was similarly immunogenic in both populations and had a clinically acceptable safety profile. Conclusion: Treatment of patients with MAGE-A3-positive unresectable stage IIIB-C/IV-M1a melanoma with the MAGE-A3 immunotherapeutic demonstrated an overall 1-year OS rate of 83.5%. GS- and GS+ patients had similar 1-year OS rates, indicating that in this study, GS was not predictive of outcome. Unexpectedly, the objective response rate was lower in this study than in other studies carried out in the same setting with the MAGE-A3 immunotherapeutic. Investigation of a GS to predict clinical benefit to adjuvant MAGE-A3 immunotherapeutic treatment is ongoing in another melanoma study. This study is registered at www.clinicatrials.gov NCT00942162